Engineers Gate Manager
LCTX icon

Engineers Gate Manager’s Lineage Cell Therapeutics LCTX Stock Holding History

Engineers Gate Manager’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,458
Closed -$10.4K – 2430
2024
Q3 		$10.4K Buy
+11,458
New +$10.6K ﹤0.01% 2056

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Engineers Gate Manager's LCTX Position: Q4 2024 in Review

Engineers Gate Manager sold out of Lineage Cell Therapeutics (LCTX) in Q4 2024, closing a stake of 11,458 shares — an estimated $10.4K sold.

Engineers Gate Manager first reported a position in LCTX in Q3 2024 and held it in 1 quarter. The position peaked at $10.4K in Q3 2024. 126 funds tracked by Wall St. Rank hold LCTX as of Q4 2024.

  • Engineers Gate Manager reported no remaining Lineage Cell Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Engineers Gate Manager sold 11,458 Lineage Cell Therapeutics shares in Q4 2024, an estimated $10.4K.
  • Engineers Gate Manager first reported a position in Lineage Cell Therapeutics in Q3 2024 and held it in 1 quarter.
  • Engineers Gate Manager's Lineage Cell Therapeutics position peaked at $10.4K in Q3 2024.
  • 126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2024.

Based on Engineers Gate Manager's 13F filing for Q4 2024, filed 14 Feb 2025.